论文部分内容阅读
目的:探讨Ezrin在大肠癌中的表达特点及其与临床病理参数的关系。方法:应用免疫组织化学S-P法检测100例大肠癌组织及11例癌旁正常黏膜中Ezrin的表达情况。结果:Ezrin阳性表达率在大肠正常粘膜、大肠癌组织中分别为36.4%、75%,差异有统计学意义(P<0.05);淋巴结转移组Ezrin阳性率(89.6%)显著高于无淋巴结转移组(61.5%)(P<0.05);在大肠癌中,Ezrin异常表达与大肠癌患者的年龄、性别、肿瘤的发生部位以及分化程度无关(P>0.05)。结论:Ezrin表达水平提高提示癌组织具有更高的浸润、侵袭能力和淋巴结转移风险,检测Ezrin有望成为判断大肠癌患者预后的新指标或治疗肿瘤转移的一个靶点。
Objective: To investigate the expression of Ezrin in colorectal carcinoma and its relationship with clinicopathological parameters. Methods: Immunohistochemical S-P method was used to detect the expression of Ezrin in 100 cases of colorectal cancer tissue and 11 cases of adjacent normal mucosa. Results: The positive rate of Ezrin in normal colorectal mucosa and colorectal cancer tissues was 36.4% and 75%, respectively (P <0.05). The positive rate of Ezrin in lymph node metastasis (89.6%) was significantly higher than that in non-lymph node metastasis Group (61.5%) (P <0.05). In colorectal cancer, the abnormal expression of Ezrin had no correlation with age, sex, tumor location and differentiation (P> 0.05). Conclusion: The increased expression of Ezrin suggests that the cancer tissue has a higher risk of invasion, invasion and lymph node metastasis. Detection of Ezrin may be a new target for the prognosis of patients with colorectal cancer or a target for the treatment of tumor metastasis.